Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. TGT

Go back to Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Inovio Pharmaceuticals (INO) PT Lowered to $6 at RBC Capital

November 15, 2024 6:33 AM EST

RBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $6.00 (from $7.00) while maintaining a Sector Perform rating.

The analyst comments "INOs 3Q print affirms INO-3107 in RRP as the companys primary focus during a time... More